NASDAQ:SPRB
Spruce Biosciences, Inc. Stock News
$0.750
-0.0199 (-2.58%)
At Close: May 17, 2024
LOS ANGELES, CA / ACCESSWIRE / April 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscience
LOS ANGELES, CA / ACCESSWIRE / March 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscienc
LOS ANGELES, CA / ACCESSWIRE / March 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscienc
LOS ANGELES, CA / ACCESSWIRE / March 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscienc
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
05:36pm, Wednesday, 27'th Mar 2024
NEW YORK , March 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or the "Company") (NASDAQ: SPRB). Such investors are advise
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
01:01pm, Wednesday, 27'th Mar 2024
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
LOS ANGELES, CA / ACCESSWIRE / March 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscienc
LOS ANGELES, CA / ACCESSWIRE / March 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Bioscienc
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
11:21am, Thursday, 21'st Mar 2024
Spruce Biosciences' (SPRB) CAHmelia-203 phase IIb study of tildacerfont in adult patients with CAH fails to meet the primary efficacy endpoint.
Why Is Spruce Biosciences (SPRB) Stock Down 78% Today?
08:28am, Thursday, 14'th Mar 2024
Spruce Biosciences (NASDAQ: SPRB ) stock is falling hard on Thursday after the biopharmaceutical company posted two new updates for investors. The first big update that has investors in SPRB stock re
Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
04:05pm, Tuesday, 30'th Jan 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocri
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
08:15am, Friday, 20'th Oct 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
04:00pm, Monday, 28'th Aug 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for ra
Best Penny Stocks To Buy? 3 To Watch With Targets Up To 400%
11:54am, Thursday, 23'rd Feb 2023
Analysts like these penny stocks but is it time to buy or not? The post Best Penny Stocks To Buy?
Penny Stocks To Buy? 4 Cheap Stocks To Watch Right Now
12:07pm, Thursday, 09'th Feb 2023
High volume penny stocks to watch right now. The post Penny Stocks To Buy?
